| Title |
Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, May 2018
|
| DOI | 10.2147/ndt.s158865 |
| Pubmed ID | |
| Authors |
Yuki Omori, Takashi Kanbayashi, Yohei Sagawa, Aya Imanishi, Ko Tsutsui, Yuya Takahashi, Masahiro Takeshima, Manabu Takaki, Seiji Nishino, Tetsuo Shimizu |
| Abstract |
Delayed sleep phase syndrome (DSPS) is a chronic dysfunction of circadian rhythm of the subject that impairs functioning in social, occupational, or other spheres. High rate of depression is found among DSPS patients. Aripiprazole (APZ), a second-generation antipsychotic, is effective in treatment of depression as well as schizophrenia. Recently, few case reports show the effectiveness of APZ in treating DSPS and non-24-hour sleep-wake rhythm disorder. Therefore, we tried to treat DSPS with depression using APZ. Twelve subjects (including four women) aged 19-64 years were included. The subjects were prescribed initially 0.5-3 mg of APZ once a day with subsequent dose adjustments. Sleep onset, midpoint of sleep, and sleep offset were significantly advanced by 1.1, 1.8, and 2.5 hours, respectively. Unexpectedly, sleep duration became significantly shorter by 1.3 hours after treatment. Their depressive moods showed an unremarkable change. Low dose of APZ advanced the sleep rhythm and reduced nocturnal sleep time in the subjects with DSPS. Since it is not easy for physicians to treat prolonged sleep duration often associated with DSPS, this medication would become a new therapeutic option for these patients. |
X Demographics
The data shown below were collected from the profiles of 39 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 5 | 13% |
| United States | 4 | 10% |
| Korea, Republic of | 2 | 5% |
| Germany | 1 | 3% |
| Romania | 1 | 3% |
| Korea, Democratic People's Republic of | 1 | 3% |
| Saudi Arabia | 1 | 3% |
| Unknown | 24 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 33 | 85% |
| Practitioners (doctors, other healthcare professionals) | 4 | 10% |
| Scientists | 1 | 3% |
| Unknown | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 18% |
| Researcher | 8 | 16% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Bachelor | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 7 | 14% |
| Unknown | 15 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 24% |
| Neuroscience | 4 | 8% |
| Psychology | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 21 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2023.
All research outputs
#1,282,676
of 25,843,331 outputs
Outputs from Neuropsychiatric Disease and Treatment
#168
of 3,151 outputs
Outputs of similar age
#27,163
of 340,440 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#3
of 80 outputs
Altmetric has tracked 25,843,331 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,151 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,440 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.